CNS Pharmaceuticals (CNSP) said Friday that a Nasdaq hearings panel has given it more time regain compliance with the exchange's minimum bid price requirement.
The company said it was granted until March 11, 2025 to regain compliance with the listing rule.
CNS shares were 1.3% higher in recent trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments